China FDA Bans Korean Drug After Disagreement On Overseas Inspection
This article was originally published in PharmAsia News
Executive Summary
In a sign of increasing confidence by Chinese regulators, CFDA banned an injectable antibiotic from Daewoong Pharmaceutical after the company rejected an overseas inspection request due to ongoing upgrades at a Korean plant.